European Biosimilars Teva launched AHZANTIVE aflibercept biosimilar to Eylea in Europe, expanding its biosimilars portfolio in ophthalmology. This signals demand in the European market and creates opportunities to partner with ophthalmology clinics, distributors, and payers, as well as cross sell with other Teva ophthalmic products and patient access programs.

Neurology Evidence Recent real world data presentations at multiple conferences show that AUSTEDO and AUSTEDO XR improve involuntary movements, daily function, and social participation in tardive dyskinesia, and reduce Huntington disease chorea with meaningful daily functioning gains. This provides a compelling evidence narrative for clinicians and payers, enabling targeted education programs, investigator initiated studies, and patient access plans to accelerate uptake.

Global Manufacturing Scale Teva's large scale manufacturing footprint and complex generics biosimilars capability position it as a reliable partner for contract manufacturing, supply agreements, and distribution collaborations across regions. Opportunities include co development of complex generics or biosimilars, optimization of supply chain, and joint market access initiatives.

Data Driven Partnerships Teva demonstrates commitment to real world evidence and post marketing data through conference presentations, suggesting openness to external data partnerships. Opportunities for BD teams include CRO collaborations, data analytics services, and payer oriented value dossiers to support product access and evidence generation.

Digital Sales Enablement The tech stack includes Veeva CRM, Batch file, and data tools, indicating readiness for digital engagement and integrated analytics. Opportunity to offer advanced CRM optimization, interoperability, and digital patient support platforms that align with Teva's sales and pharmacovigilance workflows.